CASC3 and mantle cell lymphoma: BTZ has also shown clinical efficacy in Mantle Cell Lymphoma[15] and Waldenström’s Macroglobulinemia[16], the latter also in combination with rituximab[17], indicating its effectivity in inducing cell death in earlier stages of B-cell development.